Abstract: A computing machine accesses text from a record. The computing machine identifies, using a natural language processing engine, an entity mapped to a first span of the text. The first span includes a contiguous sequence of one or more words or subwords in the text. The computing machine determines a bias category for the entity. The bias category is selected from a predefined list of bias categories. The determined bias category for the entity depends on a second span of the text. The second span includes a contiguous sequence of one or more words or subwords in the text. The second span is different from the first span.

Abstract: A computing machine accesses text from a record. The computing machine identifies, using a natural language processing engine, an entity mapped to a first span of the text. The first span includes a contiguous sequence of one or more words or subwords in the text. The computing machine determines a bias category for the entity. The bias category is selected from a predefined list of bias categories. The determined bias category for the entity depends on a second span of the text. The second span includes a contiguous sequence of one or more words or subwords in the text. The second span is different from the first span.

Abstract: The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABAB agonist, lesogaberan (AZD3355), or related compounds.

Abstract: A computing machine accesses text from a record. The computing machine identifies, using a natural language processing engine, an entity mapped to a first span of the text. The first span includes a contiguous sequence of one or more words or subwords in the text. The computing machine determines a bias category for the entity. The bias category is selected from a predefined list of bias categories. The determined bias category for the entity depends on a second span of the text. The second span includes a contiguous sequence of one or more words or subwords in the text. The second span is different from the first span.

Abstract: A computing machine accesses text from a record. The computing machine identifies, using a natural language processing engine, an entity mapped to a first span of the text. The first span includes a contiguous sequence of one or more words or subwords in the text. The computing machine determines a bias category for the entity. The bias category is selected from a predefined list of bias categories. The determined bias category for the entity depends on a second span of the text. The second span includes a contiguous sequence of one or more words or subwords in the text. The second span is different from the first span.

Abstract: The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABAB agonist, lesogaberan (AZD3355), or related compounds.

Abstract: Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLF6wt), in particular any one of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods for diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein.

Abstract: The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

Abstract: Treatment methods and compositions for the treatment of fibrosis are provided. In some embodiments, these methods include augmentation of dendritic cells for treatment of fibrosis. In some embodiments, fms-like tyrosine kinase 3 ligand (Flt3L) is used for the treatment of fibrosis and/or the augmentation of dendritic cells. In certain embodiments, the invention relates to methods for the treatment of fibrosis using Flt3L-expanded dendritic cells. In certain embodiments, the fibrosis is hepatic or pulmonary fibrosis.

Abstract: Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLFwt), in particular anyone of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein.

Abstract: Methods and compositions are provide to allow discrimination of dysplastic nodules from early HCC nodules. More specifically, it has been determined that TERT, GPC3, gankyrin, survivin, TOP2A, LYVE1, Ecadherin, IGFBP3, PDGFRA, TGFA, cyclin D1 and HGF are differentially expressed in HCC as compared to normal liver cells and liver cells that have dysplastic, non-cancerous nodules.

Abstract: A method for the treatment of hepatic fibrotic injuries caused by various diseases, viral infections or toxic agents which involves the use of glatiramer acetate as an immuno-modulatory agent. The diseases to be treated are hepatic fibrosis and hepatic cellular carcinomas. Also disclose is the use of glatiramer acetate in the treatment of inflammatory bowel diseases. Additionally, disclosed are methods for screening for immuno-modulatory agents which are useful in the treatment of hepatic fibrosis, hepatic cellular carcinomas and inflammatory bowel diseases.

Abstract: Disclosed herein is a method for treating hepatic fibrosis comprising administering to a patient in need of such treatment an amount effective to treat hepatic fibrosis of imatinib mesylate. This is based on the ability of imatinib mesylate to down regulate stellate cell activation in culture and in vivo. Hepatic fibrosis is not limited to patients with chronic Hepatitis B, Hepatitis C, non-alcoholic steatophepatitis (NASH), alcoholic liver disease, metabolic liver diseases (Wilson's disease, hemochromatosis), biliary obstruction (congenital or acquired) or liver diseases associated with fibrosis of unknown cause.

Abstract: The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

Abstract: Disclosed herein is a method for treating hepatic fibrosis comprising administering to a patient in need of such treatment an amount effective to treat hepatic fibrosis of imatinib mesylate. This is based on the ability of imatinib mesylate to down regulate stellate cell activation in culture and in vivo. Hepatic fibrosis is not limited to patients with chronic Hepatitis B, Hepatitis C, non-alcoholic steatophepatitis (NASH), alcoholic liver disease, metabolic liver diseases (Wilson's disease, hemochromatosis), biliary obstruction (congenital or acquired) or liver diseases associated with fibrosis of unknown cause.